OPANA ER
Total Payments
$224,715
Transactions
215
Doctors
13
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $22,755 | 70 | 2 |
| 2017 | $201,959 | 145 | 13 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $186,329 | 186 | 82.9% |
| Consulting Fee | $38,274 | 19 | 17.0% |
| Travel and Lodging | $106.37 | 7 | 0.0% |
| Food and Beverage | $5.35 | 3 | 0.0% |
Payments by Type
Research
$186,329
186 transactions
General
$38,386
29 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study to Validate Coded Medical Terminologies Used to Identify Opioid-Related Overdose in the Postmarketing Databases Employed in PMR Study 1B | Endo Pharmaceuticals Inc. | $128,391 | 0 |
| A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Structured Opioid Discontinuation Versus Continued Opioid Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioid Analgesic Therapy for Chronic Pain. | Endo Pharmaceuticals Inc. | $28,138 | 7 |
| A prospective investigation of the risks of opioid misuse, abuse, and addiction among patients treated with extended-releaselong acting ERLA opioids for the treatment of chronic pain Incidence and Predictors of Opioid Overdose and Death among ERLA Opioid Analgesics Users as Measured by Diagnoses and Death Records A Retrospective Database Study Study to validate coded medical terminologies used to identify opioid-related overdose in the postmarketing databases employed in PMR Study 1B | Endo Pharmaceuticals Inc. | $21,490 | 0 |
| Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication | Endo Pharmaceuticals Inc. | $5,222 | 0 |
| A MULTICENTER STUDY OF THE SAFETY, TOLERABILITY, EFFECTIVENESS AND PHARMACOKINETICS OF OXYMORPHONE HCL EXTENDED RELEASE TABLETS IN PEDIATRIC SUBJECTS REQUIRING AN AROUND THE CLOCK ATC OPIOID FOR AN EXTENDED PERIOD OF TIME | Endo Pharmaceuticals Inc. | $2,481 | 0 |
| Incidence and Predictors of Opioid Overdose and Death Among ERLA Opioid Analgesics Users as Measured by Diagnoses and Death Records - a Retrospective Database Study | Endo Pharmaceuticals Inc. | $359.03 | 1 |
| Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain | Endo Pharmaceuticals Inc. | $132.33 | 1 |
| A Prospective Investigation of the Risks of Opioid Misuse, Abuse, and Addiction Among Patients Treated With Extended-releaseLong Acting ERLA Opioids for the Treatment of Chronic Pain | Endo Pharmaceuticals Inc. | $115.88 | 1 |
Top Doctors Receiving Payments for OPANA ER
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Overland Park, KS | $184,521 | 181 |
| , MD | Pain Medicine | Salt Lake City, UT | $36,500 | 1 |
| , MD | Neurology | Philadelphia, PA | $616.75 | 5 |
| , M.D | Interventional Pain Medicine | Laguna Hills, CA | $509.31 | 3 |
| , MD | General Practice | Miami, FL | $503.04 | 1 |
| , M.D | Internal Medicine | Houston, TX | $391.33 | 1 |
| , MD | Cardiovascular Disease | Los Angeles, CA | $383.73 | 1 |
| , M.D., PH.D | Rheumatology | Jamaica Plain, MA | $359.03 | 1 |
| , MD | Physical Medicine & Rehabilitation | Mobile, AL | $299.87 | 3 |
| , M.D | Infectious Disease | San Francisco, CA | $288.75 | 1 |
| , MD | Neurology | Philadelphia, PA | $149.86 | 4 |
| , M.D., M.S | Internal Medicine | Bronx, NY | $115.88 | 8 |
| , MD | Medical Toxicology | Aurora, CO | $62.05 | 4 |
| , M.D | Family Medicine | Foley, AL | $14.16 | 1 |
Ad
Manufacturing Companies
- Endo Pharmaceuticals Inc. $224,715
Product Information
- Type Drug
- Total Payments $224,715
- Total Doctors 13
- Transactions 215
About OPANA ER
OPANA ER is a drug associated with $224,715 in payments to 13 healthcare providers, recorded across 215 transactions in the CMS Open Payments database. The primary manufacturer is Endo Pharmaceuticals Inc..
Payment data is available from 2017 to 2018. In 2018, $22,755 was paid across 70 transactions to 2 doctors.
The most common payment nature for OPANA ER is "Unspecified" ($186,329, 82.9% of total).
OPANA ER is associated with 8 research studies, including "Study to Validate Coded Medical Terminologies Used to Identify Opioid-Related Overdose in the Postmarketing Databases Employed in PMR Study 1B" ($128,391).